CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 48 enrolled
Drug / intervention
Influenza vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02268500
NCT02268500Phase 4Completed
CompareCT.gov

VAccination to Improve Clinical outComes in Heart Failure Trial (VACC-HeFT): a Feasibility Study

University of Wisconsin, Madison·interventional·Posted Oct 20, 2014·Updated Jun 9, 2021

In Brief

A Phase 4 clinical trial evaluating Influenza vaccine for Chronic Heart Failure. Completed, enrolled 48 participants across 1 site.

Detailed Summary

A multi-center, prospective, randomized, open-label blinded-endpoint trial in patients with heart failure will be conducted; 20 will be assigned to the standard dose vaccine dose and 20 patients to high dose influenza vaccine. Post-vaccine antibody measurements will be assessed, as well as tolerability differences between groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 20, 2014
Enrollment StartSep 1, 2014
Primary CompletionJan 1, 2016
Study CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.7 years ago

Interventions

Influenza vaccinebiological

Influenza vaccine